Method for suppressing the adhesion of harmful substances to the atmosphere

Abstract

To provide a method for suppressing the attachment of air pollutants, having a good feeling of use when applying an external preparation to skin, and capable of effectively suppressing the attachment of air pollutants to skin.SOLUTION: The present invention provides a method for suppressing the attachment of air pollutants, by applying an external preparation to skin to suppress the attachment of air pollutants to the skin. The external preparation contains the following component (A) and component (B), and in the external preparation, a mass ratio between the component (B) content to the component (A) content [(B) / (A)] is 9 or less. The component (A): a hydrophobic metal oxide having an average primary particle diameter dA of 800 nm or less. The component (B): ester oil.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a method for suppressing the adhesion of atmospheric hazardous substances. [Background technology]

[0002] In recent years, harmful substances suspended in the air, such as pollen from cedar and cypress trees, soot, dust, and other air pollutants, as well as yellow sand (hereinafter referred to as "air hazardous substances"), have become a problem due to their various health hazards to humans. Among these harmful air pollutants, particulate matter with a diameter of 2.5 μm or less, known as PM2.5, is composed of carbon, sulfates, nitrates, ammonium salts, and other components. Inhalation of PM2.5 and yellow sand is known to cause circulatory and respiratory diseases. It has also been pointed out that PM2.5, yellow sand, and pollen can cause skin problems by adhering to or penetrating the skin. For example, Non-Patent Document 1 contains an academic report on the skin damage caused by PM2.5. Therefore, there is a growing demand for cosmetics that protect the skin from air hazardous substances. For example, Patent Document 1 describes a skin care cosmetic that contains a specific amount of magnesium aluminometasilicate and a specific amount of an ultraviolet protection agent as a skin care cosmetic that protects the skin from external stimuli such as air pollutants. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] International Publication No. 2014 / 136993 [Non-patent literature]

[0004] [Non-Patent Document 1] Shiraiwa et al., Nature Chemistry 3, 291-295 (2011) Summary of the Invention [Problem to be solved by the invention]

[0005] The technology of Patent Document 1 describes how magnesium aluminometasilicate adsorbs air pollutants using its adsorption ability, preventing them from reaching the skin, and how its pH buffering ability neutralizes any acidic substances that may adhere to the skin, thereby reducing skin damage caused by these external stimuli. It also describes how UV protection agents effectively protect the skin from UV rays. While this technology can reduce the effects of air pollutants on the skin, it does not prevent air pollutants from adhering to the skin, and there is room for improvement. Furthermore, when inorganic powders are incorporated into topical preparations, the topical preparation may experience a rough, unpleasant feel when applied to the skin. Therefore, a pleasant feel during application is also required. The present invention aims to provide a method for inhibiting the adhesion of atmospheric hazardous substances, which provides a good feeling when applied to the skin and can effectively inhibit the adhesion of atmospheric hazardous substances to the skin. [Means for solving the problem]

[0006] The present inventors have found that the above-mentioned problems can be solved by applying to the skin an external preparation containing a hydrophobized metal oxide having an average primary particle size within a specific range and an ester oil in a specific mass ratio, rather than by adsorbing air pollutants as in Patent Document 1. This creates nano-sized irregularities on the skin surface without impairing the feel upon application, thereby suppressing the adhesion of air pollutants to the skin. That is, the present invention provides a method for inhibiting adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains the following components (A) and (B), and the mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B) / (A)] is 9 or less. Component (A): Average primary particle diameter d A Hydrophobized metal oxide with a diameter of 800 nm or less Ingredient (B): Ester oil [Effects of the Invention]

[0007] According to the method of the present invention, the topical preparation has a good feel when applied to the skin, and can effectively prevent atmospheric hazardous substances from adhering to the skin. [Brief explanation of the drawings]

[0008]

Figure 1

[0009] [Methods for preventing the adhesion of harmful substances to the atmosphere] The method for inhibiting the adhesion of atmospheric hazardous substances of the present invention is a method for inhibiting the adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, wherein the external preparation contains the following components (A) and (B), and the mass ratio [(B) / (A)] of the content of component (B) to the content of component (A) in the external preparation is 9 or less. Component (A): Average primary particle diameter d A Hydrophobized metal oxide with a diameter of 800 nm or less Ingredient (B): Ester oil In the present invention, "harmful air substances" refers to air pollutants such as pollen from cedar, cypress, etc.; soot and smoke such as sulfur oxides, soot, and nitrogen oxides, particulate matter, automobile exhaust fumes, harmful air pollutants such as benzene, trichloroethylene, and tetrachloroethylene, and particles containing volatile organic compounds (VOCs); and harmful substances (including PM2.5) floating in the air such as yellow sand. In the present invention, the term "hydrophobized metal oxide" refers to a metal oxide whose surface has been subjected to a hydrophobization treatment. In the following description, the effect of the present invention in inhibiting adhesion of atmospheric hazardous substances will be simply referred to as "adhesion inhibiting effect."

[0010] The adhesion inhibiting method of the present invention provides a good feeling when applying the topical preparation to the skin and is highly effective in inhibiting the adhesion of air hazardous substances, particularly air hazardous substances in the form of fine particles. The reason for this is not clear, but is thought to be as follows. In the present invention, by applying to the skin a metal oxide having an average primary particle size within a specific range and whose surface has been hydrophobized, nano-sized irregularities are formed on the skin surface, which reduces the contact area when atmospheric hazardous substances come into contact with the metal oxide, and is thought to effectively suppress the adhesion of atmospheric hazardous substances. In addition, the topical preparation used in the present invention contains a hydrophobized metal oxide and an ester oil as an oil agent in a specific mass ratio, and therefore, it is believed that the lubricating effect of the ester oil provides a good feeling of use without impeding the effect of inhibiting the adhesion of the above-mentioned atmospheric hazardous substances.In addition, the hydrophobized metal oxide spreads smoothly on the skin surface together with the ester oil, which is also thought to contribute to a good feeling of use.

[0011] <External preparations> The topical preparation used in the present invention contains the above-mentioned component (A) and component (B) from the viewpoint of improving the adhesion inhibitory effect and improving the feeling of use when applied to the skin.

[0012] [Component (A): Hydrophobized metal oxide] Component (A) has an average primary particle diameter d A The metal oxide is a hydrophobized metal oxide having a particle size of 800 nm or less (hereinafter also referred to as "hydrophobized metal oxide"). Average primary particle diameter d of component (A) A From the viewpoint of improving the adhesion suppression effect, the average primary particle diameter d is 800 nm or less, preferably 500 nm or less, more preferably 300 nm or less, even more preferably 200 nm or less, still more preferably 80 nm or less, and even more preferably 50 nm or less, and from the viewpoint of versatility, it is preferably 5 nm or more, more preferably 10 nm or more. AFrom the viewpoint of improving the adhesion suppression effect and from the viewpoint of versatility, the thickness is preferably 5 to 800 nm, more preferably 5 to 500 nm, even more preferably 5 to 300 nm, still more preferably 5 to 200 nm, still more preferably 5 to 80 nm, still more preferably 5 to 50 nm, and still more preferably 10 to 50 nm. The average primary particle diameter d A can be determined from an image observed with a transmission electron microscope (TEM). Specifically, the TEM is used to observe the particles at a magnification of 50,000 times, and the maximum minor diameter of 300 primary particles in the observed image is measured, and the number average value is calculated. Here, the maximum minor diameter means the longest minor diameter among the minor diameters perpendicular to the major diameter when component (A) has a shape other than a plate shape. Furthermore, when component (A) is plate-shaped, the thickness of 300 primary particles in the observed image observed under the same conditions as above is measured, and the number average value is calculated. Specifically, it is measured by the method described in the examples.

[0013] The metal oxide of component (A) is not particularly limited as long as it is one that is commonly used in external preparations such as cosmetics. Specific examples include titanium oxide, zinc oxide, cerium oxide, aluminum oxide (alumina), magnesium oxide, calcium oxide, zirconium oxide, iron oxide, and chromium oxide. Among these, from the viewpoint of imparting ultraviolet protection ability, one or more selected from titanium oxide, zinc oxide, and cerium oxide are preferred, and one or more selected from titanium oxide and zinc oxide are more preferred. When the metal oxide of component (A) is titanium oxide, the crystal structure of the titanium oxide may be any of anatase, rutile, and brookite, but from the viewpoint of versatility, the rutile or anatase structure is preferred.

[0014] The shape of component (A) may be spherical, spindle-shaped, plate-shaped, needle-shaped, etc. Among these, spherical, spindle-shaped, and plate-shaped shapes are preferred from the viewpoint of improving the adhesion suppression effect. When the metal oxide of component (A) is titanium oxide, it is preferably spindle-shaped from the viewpoint of improving the adhesion suppression effect. When the metal oxide of component (A) is zinc oxide, it is preferably spherical or plate-shaped from the viewpoint of improving the adhesion suppression effect. The component (A) is present in the form of particles having the average primary particle diameter d A As long as the above range is satisfied, the particles may be in the form of primary particles, or may be in the form containing aggregates (secondary particles) formed by aggregation of primary particles.

[0015] The topical preparation used in the present invention contains the hydrophobized component (A), which improves the dispersibility of component (A) in the topical preparation containing component (B), thereby improving the adhesion-inhibiting effect. Examples of hydrophobic treatments include fatty acid treatment, alkylalkoxysilane treatment, silicone treatment, treatment with fluorine-containing compounds such as perfluoroalkyl phosphate esters, perfluoroalcohols, and perfluoroalkylalkoxysilanes, treatment with amino acids such as N-acylglutamic acid, and alkyl phosphate ester treatment. Among these, fatty acid treatment, alkylalkoxysilane treatment, and silicone treatment are preferred from the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect. That is, from the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect, component (A) is preferably one or more selected from the following components (A1), (A2), and (A3): Component (A1): Average primary particle diameter d A A fatty acid-treated metal oxide having a diameter of 800 nm or less Component (A2): Average primary particle diameter d A Alkylalkoxysilane-treated metal oxides with a diameter of 800 nm or less Component (A3): Average primary particle diameter d A Siliconized metal oxide with a diameter of 800 nm or less

[0016] Examples of surface treatment agents used in the fatty acid treatment of component (A1) include linear or branched fatty acids having from 12 to 22 carbon atoms. Among these, from the viewpoint of improving the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect, linear or branched higher fatty acids having from 14 to 22 carbon atoms are preferred, linear or branched higher fatty acids having from 16 to 20 carbon atoms are more preferred, and stearic acid and isostearic acid are even more preferred. The surface treatment agent used for the alkylalkoxysilane treatment of component (A2) is preferably one having a linear or branched alkyl group having from 6 to 20 carbon atoms, from the viewpoint of increasing the dispersibility of component (A) in the topical agent containing component (B) and improving the adhesion suppression effect, and octyltriethoxysilane and octyltrimethoxysilane are more preferred.

[0017] Examples of surface treatment agents used in the silicone treatment of component (A3) include various silicone oils such as methylpolysiloxane, dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, methylcyclopolysiloxane, dodecamethylcyclohexasiloxane, tetradecamethylhexasiloxane, dimethylsiloxane / methyl(polyoxyethylene)siloxane / methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane / methyl(polyoxyethylene)siloxane copolymer, dimethylsiloxane / methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane / methylcetyloxysiloxane copolymer, dimethylsiloxane / methylstearoxysiloxane copolymer, and alkyl acrylate / dimethicone copolymer. Among these, methylhydrogenpolysiloxane and dimethylpolysiloxane are preferred from the viewpoint of improving the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion suppression effect.

[0018] The above-mentioned surface treatment agents can be used alone or in combination of two or more. The amount of hydrophobic treatment is preferably 0.1% by mass or more, and preferably 40% by mass or less, more preferably 30% by mass or less, relative to component (A), from the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect. In the present invention, the mass, coating amount and average primary particle diameter d A is the mass including the surface treatment agent, the coating amount, and the average primary particle diameter d A means.

[0019] When component (A) is hydrophobized titanium oxide, the content of TiO2 in the hydrophobized titanium oxide is preferably 60% by mass or more, more preferably 70% by mass or more, and preferably less than 100% by mass, from the viewpoint of improving the adhesion suppression effect. When component (A) is hydrophobized zinc oxide, the ZnO content in the hydrophobized zinc oxide is preferably 60% by mass or more, more preferably 70% by mass or more, and preferably less than 100% by mass, from the viewpoint of improving the adhesion suppression effect.

[0020] From the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect, component (A) is preferably one or more selected from fatty acid-treated titanium oxide and fatty acid-treated zinc oxide as component (A1), alkylalkoxysilane-treated titanium oxide and alkylalkoxysilane-treated zinc oxide as component (A2), and silicone-treated titanium oxide and silicone-treated zinc oxide as component (A3), more preferably one or more selected from alkylalkoxysilane-treated titanium oxide and alkylalkoxysilane-treated zinc oxide as component (A2), and silicone-treated titanium oxide and silicone-treated zinc oxide as component (A3), and even more preferably one or more selected from alkylalkoxysilane-treated titanium oxide and alkylalkoxysilane-treated zinc oxide as component (A2).

[0021] Commercially available products of component (A1) include "STR-100C-LF" (stearic acid-treated titanium oxide) manufactured by Sakai Chemical Industry Co., Ltd.; "MPT-171" (stearic acid-treated titanium oxide) manufactured by Ishihara Sangyo Kaisha, Ltd.; and "MT-100TV" (stearic acid-treated titanium oxide) and "MT-100Z" (stearic acid-treated titanium oxide) manufactured by Teika Corporation. Commercially available products of component (A2) include "STR-100C-OTS" (titanium oxide treated with octyltriethoxysilane), "STR-100W-OTS" (titanium oxide treated with octyltriethoxysilane), "FINEX-50-OTS" (zinc oxide treated with octyltriethoxysilane), and "FINEX-30-OTS" (zinc oxide treated with octyltriethoxysilane), all manufactured by Sakai Chemical Industry Co., Ltd. Commercially available products of component (A3) include "STR-100A-LP" (silicone-treated titanium oxide) and "FINEX-50-LP™" (silicone-treated zinc oxide) manufactured by Sakai Chemical Industry Co., Ltd.; "JR-800S" (silicone-treated titanium oxide), "MPY-70M" (silicone-treated titanium oxide), "MICRO ZINC OXIDE MZ-504R3M" (silicone-treated zinc oxide), and "MT-600KS" (silicone-treated zinc oxide) manufactured by Teika Corporation; and "D-FZN" (silicone-treated zinc oxide) manufactured by Daito Kasei Kogyo Co., Ltd.

[0022] [Component (B): Ester oil] Component (B) is an oil agent, which is an ester oil. Examples of the ester oil include synthetic ester oils and natural fats and oils. Examples of component (B) include esters of monocarboxylic acids and monohydric alcohols, esters of monocarboxylic acids and polyhydric alcohols, and esters of polycarboxylic acids and monohydric alcohols.

[0023] Examples of the ester of a monovalent carboxylic acid and a monohydric alcohol include esters represented by the following general formula (1). R 1 -COO-R 2 (1) In the general formula (1), R 1represents a linear or branched alkyl or alkenyl group having 1 to 25 carbon atoms, or an aromatic hydrocarbon group having 6 to 24 carbon atoms, which may be substituted with a hydroxyl group; R 2 represents a linear or branched alkyl or alkenyl group having 1 to 30 carbon atoms.

[0024] R 1 When is an alkyl group or an alkenyl group, the number of carbon atoms is preferably 7 or more, more preferably 9 or more, and even more preferably 11 or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 23 or less, more preferably 21 or less, and even more preferably 19 or less, from the same viewpoint as above. R 1 When the aromatic hydrocarbon group is an aromatic hydrocarbon group, the number of carbon atoms is preferably 8 or more, more preferably 10 or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 22 or less, more preferably 20 or less, from the same viewpoint as above. R 2 The number of carbon atoms is preferably 2 or more from the viewpoint of improving the feel when applied to the skin, and is preferably 28 or less, more preferably 20 or less, and even more preferably 18 or less, from the same viewpoint as above. In addition, from the viewpoint of improving the feeling of use when applied to the skin, 1 and R 2 At least one of them is preferably a branched alkyl group.

[0025] Specific examples of the ester represented by the general formula (1) include myristyl 2-ethylhexanoate, cetyl 2-ethylhexanoate, stearyl 2-ethylhexanoate, isodecyl octanoate, cetyl octanoate, isocetyl octanoate, isononyl isononanoate, isotridecyl isononanoate, hexyldecyl dimethyloctanoate, hexyl laurate, isopropyl myristate, isotridecyl myristate, 2-hexyldecyl myristate, myristyl myristate, octyldodecyl myristate, isopropyl palmitate, 2-ethylhexyl palmitate, 2-hexyldecyl palmitate, Examples of the surfactant include one or more selected from 2-heptylundecyl palmitate, butyl stearate, 2-ethylhexyl stearate, stearyl stearate, isocetyl stearate, cetyl stearate, isocetyl isostearate, cholesteryl isostearate, decyl oleate, oleyl oleate, octyldodecyl oleate, lanolin acetate, cholesteryl hydroxystearate, isopropyl lanolinate, cholesteryl lanolinate, methyl castor oil fatty acid (methyl ricinoleate), cetyl lactate, myristyl lactate, and alkyl benzoate (alkyl having 12 to 15 carbon atoms).

[0026] Examples of the ester of a monocarboxylic acid and a monohydric alcohol include an ester represented by the following general formula (2). R 3 -COO-(AO) n -R 4 (2) In the general formula (2), R 3 represents a linear or branched alkyl or alkenyl group having 1 to 25 carbon atoms, which may be substituted with a hydroxyl group; R 4 represents an aromatic hydrocarbon group having 6 to 24 carbon atoms, AO represents an alkyleneoxy group having 2 to 4 carbon atoms, and n represents the average number of moles added of 1 to 50. R 3From the viewpoint of improving the feel when applied to the skin, preferably has 7 or more carbon atoms, and from the same viewpoint as above, is an alkyl group preferably having 23 or less carbon atoms, more preferably 21 or less, and even more preferably 19 or less. R 4 From the viewpoint of improving the feel when applied to the skin, preferably has 6 or more carbon atoms, and from the same viewpoint as above, is preferably an aromatic hydrocarbon group having 22 or less, more preferably 20 or less, even more preferably 18 or less, and even more preferably a benzyl group. The AO group is preferably a propyleneoxy group from the viewpoint of improving the feel when applied to the skin, and from the same viewpoint as above, n is preferably 1 or more and 10 or less, more preferably 1 or more and 5 or less. Specific examples of the ester represented by the general formula (2) include an ester of myristic acid and a 3-mol propylene oxide adduct of benzyl alcohol ("Crodamol STS" manufactured by Croda), an ester of 2-ethylhexanoic acid and a 3-mol propylene oxide adduct of benzyl alcohol ("Crodamol SFX" manufactured by Croda), and the like.

[0027] Examples of the ester of a monovalent carboxylic acid and a polyhydric alcohol include the ester represented by the following general formula (3). R 5 -(OCOR 6 ) p (3) In the general formula (3), R 5 represents a polyhydric alcohol residue, preferably a linear or branched hydrocarbon group having from 2 to 10 carbon atoms; R 6 represents a monocarboxylic acid residue having 1 to 25 carbon atoms, and p represents an integer of 2 to 10. In addition, R 5 may have an ether bond. Also, p is preferably the same number as the number of hydroxy groups in the polyhydric alcohol. R 6From the viewpoint of improving the feel when applied to the skin, preferably has 7 or more carbon atoms, more preferably 9 or more, and even more preferably 11 or more carbon atoms, and from the same viewpoint as above, is an alkyl group preferably having 23 or less carbon atoms, more preferably 21 or less, and even more preferably 19 or less carbon atoms.

[0028] Examples of the ester represented by the general formula (3) include neopentyl glycol dicaprate, neopentyl glycol di-2-ethylhexanoate, propanediol di(caprylic / capric acid), propanediol diisostearate, ethylene glycol di-2-ethylhexanoate, glyceryl tri(caprylic / capric acid), glyceryl tri-2-ethylhexanoate, glyceryl tri-2-heptylundecanoate, glyceryl trimyristate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentaerythritol tetra-2-ethylhexanoate, dipentaerythritol fatty acid, and natural fats and oils. Examples of natural oils include castor oil, cacao oil, mink oil, avocado oil, olive oil, sunflower oil, camellia oil, apricot kernel oil, almond oil, wheat germ oil, Theobroma grandiflorum seed oil, grape seed oil, babassu oil, jojoba oil, macadamia nut oil, camellia sinensis oil, shea butter oil, camellia recutita seed oil, and meadowfoam oil.

[0029] Examples of the ester of a polycarboxylic acid and a monohydric alcohol include an ester represented by the following general formula (4). R 7 -(COOR 8 ) q (4) In the general formula (4), R 7 is a polycarboxylic acid residue having 2 to 10 carbon atoms, and R 8 represents a monohydric alcohol residue having 1 to 25 carbon atoms, and q is an integer of 2 to 10. Preferably, q is the same number as the number of carboxy groups in the polycarboxylic acid. R 8From the viewpoint of providing a good feeling when applied to the skin, the saturation index is preferably 3 or more, more preferably 7 or more, and from the same viewpoint as above, it is preferably 23 or less, more preferably 21 or less, and even more preferably 19 or less. Specific examples include diisostearyl malate, di-2-ethylhexyl succinate, diisobutyl adipate, di-2-heptylundecyl adipate, di-2-hexyldecyl adipate, di-2-ethylhexyl sebacate, and diisopropyl sebacate.

[0030] From the viewpoint of protecting the skin from damage caused by ultraviolet rays, component (B) may be an ester-based ultraviolet absorber that has ultraviolet absorbing ability due to its structure. Examples of the ester-based UV absorbers include salicylic acid-based UV absorbers such as homomenthyl salicylate, octyl salicylate, and triethanolamine salicylate; para-aminobenzoic acid-based UV absorbers such as para-aminobenzoic acid, ethyl dihydroxypropyl para-aminobenzoate, glyceryl para-aminobenzoate, octyl dimethyl para-aminobenzoate, amyl dimethyl para-aminobenzoate, and 2-ethylhexyl dimethyl para-aminobenzoate; 2-ethylhexyl para-methoxycinnamate (e.g., "Uvinal MC80" manufactured by BASF Japan Ltd.), glyceryl di-para-methoxycinnamate mono-2-ethylhexanoate, methyl 2,5-diisopropylcinnamate, and 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine(ethyl Examples of the ultraviolet absorber include cinnamic acid-based ultraviolet absorbers such as methyl parahydroxycinnamate (hexyl triazone) (e.g., "Uvinal T150" manufactured by BASF Japan Ltd.), bis(trimethylsiloxy)silylisopentyl methyl trimethoxycinnamate, a mixture of isopropyl paramethoxycinnamate and diisopropyl cinnamate, and diethanolamine p-methoxyhydrocinnamate; octocrylene (e.g., "Parasol 340" manufactured by DSM Nutrition Japan Co., Ltd.); 2-ethylhexyl dimethoxybenzylidene dioxoimidazolidinepropionate (e.g., "Soft Shade DH" manufactured by Ajinomoto Co., Inc.); cinoxate; methyl-O-aminobenzoate; and diethylaminohydroxybenzoylhexyl benzoate (e.g., "Uvinal Aplus" and "Uvinal A Plus GRANULAR" manufactured by BASF Japan Ltd.).

[0031] From the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, component (B) is preferably an ester oil that is liquid at 25°C. An ester oil that is liquid at 25°C is an ester oil having a melting point of 25°C or lower. That is, component (B) is preferably an ester oil that is fluid at 25°C under 1 atmosphere. Specifically, it is preferably an ester represented by the general formula (1) or (3), and more preferably one or more selected from isopropyl palmitate, isononyl isononanoate, neopentyl glycol dicaprate, neopentyl glycol di-2-ethylhexanoate, and glyceryl tri-2-ethylhexylate. When an ester-based UV absorber is used as component (B), component (B) is preferably one or more selected from 2-ethylhexyl paramethoxycinnamate, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine, and diethylaminohydroxybenzoylhexylbenzoate, from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin.

[0032] In addition to component (A) and component (B), the topical preparation may contain cosmetic or medicinal components used depending on the intended use of the topical preparation, or components commonly used in topical preparations such as skin cosmetics, as appropriate, within the scope of the present invention. Examples of such components include oils, antioxidants, ultraviolet absorbers, surfactants, thickeners, pH adjusters, disinfectants, anti-inflammatory agents, preservatives, colorants, chelating agents, moisturizers, pearlizing agents, ceramides, antiperspirants, fragrances, etc.

[0033] [Component (C): Non-volatile oil other than component (B)] The topical preparation may further contain, as component (C), a non-volatile oil other than component (B). In the present invention, "non-volatile" means that the amount of evaporation at 25°C in 6 hours, as measured by the following method, is less than 20%. Measurement method: Place a 90mm diameter filter paper in a 120mm diameter glass dish, place 1g of sample on the filter paper, and store in a room at 65% RH (25°C) for 6 hours. Measure the mass of the sample before and after storage, and calculate the amount of evaporation using the following formula. Evaporation amount (%) = (sample mass before storage - sample mass after storage) / sample mass before storage x 100 Component (C) may be one or more selected from hydrocarbon oils, silicone oils, higher fatty acids, and higher alcohols. Among these, one or more selected from non-volatile hydrocarbon oils (C1) (hereinafter also referred to as "component (C1)") and non-volatile silicone oils (C2) (hereinafter also referred to as "component (C2)") are preferred.

[0034] As component (C1), from the viewpoint of providing a good feeling when applied to the skin, saturated or unsaturated hydrocarbons having 18 or more carbon atoms are preferred. Specific examples of component (C1) include hydrocarbon oils that are liquid at 25°C, such as squalene, squalane, liquid paraffin, hydrogenated polyisobutene (liquid isoparaffin, heavy liquid isoparaffin), liquid ozokerite, α-olefin oligomer, cycloparaffin, polybutene, and pristane; and hydrocarbon oils that are solid at 25°C, such as petrolatum, ceresin, ozokerite, paraffin wax, microcrystalline wax, and polyethylene wax. Component (C1) can be used singly or in combination of two or more. Among these, from the viewpoint of providing a good feeling when applied to the skin, hydrocarbon oils that have no melting point and are liquid at 25°C and have a kinematic viscosity of 5mm at 25°C are preferred. 2 / s or more 100,000mm 2 Hydrocarbon oils of 1 / s or less are more preferred, hydrogenated polyisobutene is even more preferred, and liquid isoparaffin is even more preferred. The kinematic viscosity of component (C1) at 25°C is more preferably 6 mm from the viewpoint of providing a good feel when applied to the skin. 2 / s or more, and from the same viewpoint as above, it is more preferable that 2 / s or less, and even more preferably 5,000 mm 2 / s or less, and even more preferably 1,000 mm 2 / s or less, and even more preferably 500 mm 2 / s or less, and even more preferably 300 mm 2 / s or less, and even more preferably 100 mm 2 / s or less, and even more preferably 50 mm 2 / s or less, and even more preferably 30 mm 2 / s or less. The kinematic viscosity of component (C1) at 25°C can be measured using an Ubbelohde viscometer in accordance with ASTM D 445-46T or JIS Z 8803. Commercially available products of component (C1) include "Pearleam EX" (liquid isoparaffin) manufactured by NOF Corporation.

[0035] Component (C2) is a non-volatile silicone oil, and specific examples include linear organopolysiloxanes such as dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, and dimethiconol (dimethylpolysiloxanes terminated at both ends with hydroxy groups); modified silicones such as amino-modified silicones (dimethylpolysiloxanes having amino groups in the molecule) and polyglycerin-modified silicones having branched polyglycerol chains at both ends; amino-derivative silicones; and liquid, semi-solid, or solid silicone oils such as silicone wax. Component (C2) can be used alone or in combination of two or more. Of these, component (C2) is preferably a linear organopolysiloxane, more preferably a dimethylpolysiloxane, from the viewpoint of providing a good feel when applied to the skin.

[0036] As component (C2), from the viewpoint of improving the feeling of use when applied to the skin and improving the adhesion suppression effect, a kinematic viscosity of 5mm at 25°C is used. 2 / s or more 100,000mm 2 Silicone oils with a viscosity of 1 / s or less are preferred. The kinematic viscosity of component (C2) at 25°C is preferably 6 mm from the viewpoint of providing a good feeling when applied to the skin.2 / s or more, and from the viewpoint of improving the adhesion suppression effect and improving the feeling of use when applied to the skin, it is more preferably 10,000 mm 2 / s or less, more preferably 5,000 mm 2 / s or less, and even more preferably 1,000 mm 2 / s or less, and even more preferably 500 mm 2 / s or less, and even more preferably 300 mm 2 / s or less, and even more preferably 100 mm 2 / s or less, and even more preferably 50 mm 2 / s or less, and even more preferably 30 mm 2 / s or less. The kinematic viscosity of component (C2) at 25°C can be measured in the same manner as above. Commercially available products of component (C2) include "KF-96A-6cs" (dimethylpolysiloxane) and "KF-96A-10cs" (dimethylpolysiloxane) manufactured by Shin-Etsu Chemical Co., Ltd.

[0037] [Component (D): Volatile oil] The topical preparation may further contain a volatile oil as component (D). In the present invention, "volatile" means that the amount of evaporation at 25°C in 6 hours, as measured by the above-mentioned method, is more than 20%.

[0038] Examples of component (D) include volatile silicone oils and volatile hydrocarbon oils. The volatile silicone oil in the present invention is a silicone oil having a kinematic viscosity of 5 mm at 25°C. 2 Preferably, the kinematic viscosity of component (D) at 25°C is less than 1 / s. The kinematic viscosity of component (D) at 25°C can be measured in the same manner as above. Volatile silicone oils include linear organopolysiloxanes and cyclic organopolysiloxanes. Specific examples of linear organopolysiloxanes include octamethyltrisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane, and 1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy]-trisiloxane. Examples of cyclic organopolysiloxanes include 4- to 6-membered cyclic siloxanes having an alkyl group having 1 to 5 carbon atoms as a substituent, and specific examples include octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane. Commercially available volatile silicone oils include Shin-Etsu Chemical Co., Ltd.'s "KF-96A-1cs" (octamethyltrisiloxane), "KF-96L-1.5cs" (decamethyltetrasiloxane), "KF-96L-2cs" (dodecamethylpentasiloxane), "KF-995" (decamethylcyclopentasiloxane), and "TMF-1.5" (1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy]trisiloxane); and Dow Corning Toray Co., Ltd.'s "SH200C Fluid 1cs" (octamethyltrisiloxane), "SH200C Fluid 1.5cs" (decamethyltetrasiloxane), "SH200C Fluid 2cs" (dodecamethylpentasiloxane), and "SH245 Fluid" (decamethylcyclopentasiloxane); and "TSF405A" (decamethylcyclopentasiloxane) manufactured by Momentive Performance Materials.

[0039] The volatile hydrocarbon oil is preferably a saturated or unsaturated hydrocarbon oil having from 8 to 16 carbon atoms, and examples thereof include paraffinic hydrocarbon oils such as n-decane, n-undecane, and n-dodecane; isoparaffinic hydrocarbon oils such as isodecane, isododecane, and hydrogenated polyisobutene (light liquid isoparaffin); and cyclic paraffinic hydrocarbon oils such as cyclodecane and cyclododecane.

[0040] [Production of topical preparations] The topical preparation used in the present invention can be produced by a known method, as appropriate, depending on the formulation of the topical preparation. For example, component (A), component (B), and, if necessary, the other components described above, are blended and stirred and mixed using a disperser or the like. When the topical preparation is a water-in-oil (W / O) type or an oil-in-water (O / W) type, which will be described later, a method can be used in which an aqueous phase and an oil phase are prepared separately and then mixed together.

[0041] (Content of ingredient (A) in topical preparation) The content of component (A) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy. More specifically, the content of component (A) is preferably 1 to 40% by mass, more preferably 2 to 35% by mass, and even more preferably 3 to 30% by mass from the viewpoint of improving the adhesion-inhibiting effect and from the viewpoint of improving the feel when applied to the skin.

[0042] (Total content of ingredients (A1), (A2) and (A3) in the topical preparation) The total content of components (A1), (A2), and (A3) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy. More specifically, the total content of components (A1), (A2), and (A3) is preferably 1 to 40% by mass, more preferably 2 to 35% by mass, and even more preferably 3 to 30% by mass, from the viewpoint of improving the adhesion-inhibiting effect and from the viewpoint of improving the feel when applied to the skin.

[0043] (Content of ingredient (B) in topical preparation) From the viewpoint of improving the feel when applied to the skin, the content of component (B) in the topical preparation is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 1% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more; and from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect, it is preferably 60% by mass or less, more preferably 50% by mass or less, even more preferably 40% by mass or less, even more preferably 30% by mass or less, even more preferably 25% by mass or less, even more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less.

[0044] (Mass ratio [(B) / (A)]) The mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B) / (A)] is 9 or less, preferably 8 or less, more preferably 6 or less, even more preferably 4 or less, and still more preferably 3 or less, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more, from the viewpoint of improving the feel when applied to the skin. More specifically, the mass ratio [(B) / (A)] is preferably 9 or less and 0.01 or more, more preferably 8 or less and 0.01 or more, even more preferably 6 or less and 0.05 or more, still more preferably 4 or less and 0.05 or more, still more preferably 4 or less and 0.1 or more, and even more preferably 3 or less and 0.1 or more, from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin.

[0045] (Mass ratio [(B) / [(A1)+(A2)+(A3)]]) When component (A) is one or more selected from component (A1), component (A2), and component (A3), the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more, from the viewpoint of improving the feel when applied to the skin. More specifically, the mass ratio [(B) / [(A1)+(A2)+(A3)]] is preferably 9 or less and 0.01 or more, more preferably 8 or less and 0.01 or more, even more preferably 6 or less and 0.05 or more, still more preferably 4 or less and 0.05 or more, still more preferably 4 or less and 0.1 or more, and still more preferably 3 or less and 0.1 or more, from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin.

[0046] When the topical preparation further contains component (C1) (non-volatile hydrocarbon oil), the mass ratio α1 (=[(C1) / (A)]) of the content of component (C1) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 3.5 or less, more preferably 3 or less, even more preferably 2.5 or less, and even more preferably 2 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.05 or more, and even more preferably 0.1 or more. Furthermore, the mass ratio β1 (=[[(B)+(C1)] / (A)]) of the total content of component (B) and component (C1) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more. From the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, the mass ratio α1 is preferably 3.5 or less and 0.01 or more, and the mass ratio β1 is 9 or less and 0.01 or more, more preferably 3 or less and 0.03 or more, and the mass ratio β1 is 8 or less and 0.01 or more, even more preferably 2.5 or less and 0.05 or more, and the mass ratio β1 is 6 or less and 0.05 or more, still more preferably 2 or less and 0.1 or more, and the mass ratio β1 is 4 or less and 0.1 or more, and even more preferably 2 or less and 0.1 or more, and the mass ratio β1 is 3 or less and 0.1 or more.

[0047] When the topical preparation further contains component (C1), the preferred range of the mass ratio αI (=[(C1) / [(A1)+(A2)+(A3)]]) of the content of component (C1) to the total content of components (A1), (A2), and (A3) in the topical preparation is the same as the preferred range of the mass ratio α1. Furthermore, the preferred range of the mass ratio βI (=[[(B)+(C1)] / [(A1)+(A2)+(A3)]]) of the total content of component (B) and component (C1) to the total content of component (A1), component (A2), and component (A3) in the topical preparation is the same as the preferred range of the mass ratio β1. From the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, the mass ratio αI is preferably 3.5 or less and 0.01 or more, and the mass ratio βI is 9 or less and 0.01 or more, more preferably 3 or less and 0.03 or more, and the mass ratio βI is 8 or less and 0.01 or more, even more preferably 2.5 or less and 0.05 or more, and the mass ratio βI is 6 or less and 0.05 or more, even more preferably 2 or less and 0.1 or more, and the mass ratio βI is 4 or less and 0.1 or more, and even more preferably 2 or less and 0.1 or more, and the mass ratio βI is 3 or less and 0.1 or more.

[0048] When the topical preparation further contains component (C2) (non-volatile silicone oil), the mass ratio α2 (= [(C2) / (A)]) of the content of component (C2) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion inhibitory effect, preferably 0.85 or less, more preferably 0.80 or less, even more preferably 0.75 or less, and even more preferably 0.70 or less. From the viewpoint of improving the feel when applied to the skin, it is preferably 0.01 or more, more preferably 0.02 or more, and even more preferably 0.03 or more. Furthermore, the mass ratio β2 (=[[(B)+(C2)] / (A)]) of the total content of component (B) and component (C2) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more. From the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, the mass ratio α2 is preferably 0.85 or less and 0.01 or more, and the mass ratio β2 is 9 or less and 0.01 or more, more preferably 0.80 or less and 0.01 or more, and the mass ratio β2 is 8 or less and 0.01 or more, even more preferably 0.75 or less and 0.02 or more, and the mass ratio β2 is 6 or less and 0.05 or more, still more preferably 0.70 or less and 0.03 or more, and the mass ratio β2 is 4 or less and 0.1 or more, and even more preferably 0.70 or less and 0.03 or more, and the mass ratio β2 is 3 or less and 0.1 or more.

[0049] When the topical preparation further contains component (C2), the preferred range of the mass ratio αII (=[(C2) / [(A1)+(A2)+(A3)]]) of the content of component (C2) to the total content of components (A1), (A2), and (A3) in the topical preparation is the same as the preferred range of the mass ratio α2. Furthermore, the preferred range of the mass ratio βII (=[[(B)+(C2)] / [(A1)+(A2)+(A3)]]) of the total content of component (B) and component (C2) to the total content of component (A1), component (A2), and component (A3) in the topical preparation is the same as the preferred range of the mass ratio β2. From the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, the mass ratio αII is preferably 0.85 or less and 0.01 or more, and the mass ratio βII is 9 or less and 0.01 or more, more preferably 0.80 or less and 0.01 or more, and the mass ratio βII is 8 or less and 0.01 or more, even more preferably 0.75 or less and 0.02 or more, and the mass ratio βII is 6 or less and 0.05 or more, even more preferably 0.70 or less and 0.03 or more, and the mass ratio βII is 4 or less and 0.1 or more, and even more preferably 0.70 or less and 0.03 or more, and the mass ratio βII is 3 or less and 0.1 or more.

[0050] When the topical preparation further contains component (C1) and component (C2), the mass ratio α(1-2) (=[[(C1)+(C2)] / (A)]) of the total content of component (C1) and component (C2) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion inhibitory effect, preferably 3.5 or less, more preferably 3 or less, even more preferably 2.5 or less, and still more preferably 2 or less. From the viewpoint of improving the feel when applied to the skin, it is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.05 or more, and still more preferably 0.1 or more. Furthermore, the mass ratio β(1-2) (=[[(B)+(C1)+(C2)] / (A)]) of the total content of component (B), component (C1), and component (C2) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more. From the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, the mass ratio α2 is preferably 0.85 or less and 0.01 or more, the mass ratio α(1-2) is 3.5 or less and 0.01 or more, and the mass ratio β(1-2) is 9 or less and 0.01 or more, more preferably the mass ratio α2 is 0.80 or less and 0.01 or more, the mass ratio α(1-2) is 3 or less and 0.03 or more, and the mass ratio β(1-2) is 8 or less and 0.01 or more, and even more preferably the mass ratio α2 is The mass ratio α2 is 0.75 or less and 0.02 or more, and the mass ratio α(1-2) is 2.5 or less and 0.05 or more, and the mass ratio β(1-2) is 6 or less and 0.05 or more, even more preferably the mass ratio α2 is 0.70 or less and 0.03 or more, and the mass ratio α(1-2) is 2 or less and 0.1 or more, and the mass ratio β(1-2) is 4 or less and 0.1 or more, even more preferably the mass ratio α2 is 0.70 or less and 0.03 or more, and the mass ratio α(1-2) is 2 or less and 0.1 or more, and the mass ratio β(1-2) is 3 or less and 0.1 or more.

[0051] When the topical preparation further contains component (C1) and component (C2), the preferred range of the mass ratio α(I-II) (=[[(C1)+(C2)] / [(A1)+(A2)+(A3)]]) of the total content of component (C1) and component (C2) to the total content of component (A1), component (A2), and component (A3) in the topical preparation is the same as the preferred range of the mass ratio α(1-2). Furthermore, the preferred range of the mass ratio β(I-II) (=[[(B)+(C1)+(C2)] / [(A1)+(A2)+(A3)]]) of the total content of component (B), component (C1), and component (C2) to the total content of component (A1), component (A2), and component (A3) in the topical preparation is the same as the preferred range of the mass ratio β(1-2). From the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, the mass ratio αII is preferably 0.85 or less and 0.01 or more, the mass ratio α(I-II) is 3.5 or less and 0.01 or more, and the mass ratio β(I-II) is 9 or less and 0.01 or more, more preferably the mass ratio αII is 0.80 or less and 0.01 or more, the mass ratio α(I-II) is 3 or less and 0.03 or more, and the mass ratio β(I-II) is 8 or less and 0.01 or more, and even more preferably the mass ratio αII is 0. Preferably, the mass ratio αII is 0.02 or more and the mass ratio α(I-II) is 0.05 or more and the mass ratio β(I-II) is 0.05 or more and the mass ratio α(I-II) is 0.05 or more and the mass ratio β(I-II) is 0.05 or more and the mass ratio α(I-II) is 0.03 or more and the mass ratio α(I-II) is 0.1 or more and the mass ratio β(I-II) is 0.1 ...3 or less and the mass ratio α(I-II).

[0052] (Content of component (C1)) When the topical preparation contains component (C1), the content of component (C1) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, even more preferably 3% by mass or more, and even more preferably 5% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

[0053] (Content of component (C2)) When the topical preparation contains component (C2), the content of component (C2) in the topical preparation is preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and even more preferably 1% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 15% by mass or less, more preferably 10% by mass or less, even more preferably 8% by mass or less, and even more preferably 6% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

[0054] (Content of component (D)) When the topical preparation contains component (D), the content of component (D) in the topical preparation is preferably 20% by mass or more, more preferably 25% by mass or more, even more preferably 30% by mass or more, from the viewpoint of improving the adhesion suppression effect, and is preferably 95% by mass or less, more preferably 90% by mass or less, even more preferably 85% by mass or less.

[0055] The form of the topical agent used in the present invention can be selected appropriately from among oil-based types using a single oil phase as the dispersion medium, oil-in-water types (hereinafter also referred to as "O / W types"), and water-in-oil types (hereinafter also referred to as "W / O types"). In the present invention, the topical preparation can be applied to, for example, the skin or hair. From the viewpoint of adhesion-inhibiting effect, the topical preparation is preferably a cosmetic, more preferably a skin cosmetic. The dosage form of the external preparation is not particularly limited, and it may be in any dosage form such as liquid, foam, paste, cream, or solid. When the topical preparation is in the form of an oil, the content and mass ratio of each component are as described above. When the topical preparation is in the form of a W / O or O / W type, the content and mass ratio of each component are as follows:

[0056] (Content and mass ratio of each component in the case of water-in-oil (W / O) type) When the topical preparation is a W / O type, the content of component (A) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy.

[0057] When the topical preparation is a W / O type, the total content of component (A1), component (A2), and component (A3) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy.

[0058] When the topical preparation is a W / O type, the content of component (B) in the topical preparation is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 1% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, and is preferably 30% by mass or less, more preferably 25% by mass or less, even more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less, from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin.

[0059] When the topical preparation is a W / O type, the mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B) / (A)] is, from the viewpoint of improving the adhesion-inhibiting effect, 9 or less, preferably 8 or less, more preferably 6 or less, even more preferably 4 or less, and even more preferably 3 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more.

[0060] When the topical preparation is a W / O type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more, from the viewpoint of improving the feel when applied to the skin.

[0061] When the topical preparation is a W / O type and contains component (C1), the content of component (C1) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, and even more preferably 8% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 16% by mass or less, and even more preferably 12% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

[0062] When the topical preparation is a W / O type and contains component (C2), the content of component (C2) in the topical preparation is preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and even more preferably 1% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 15% by mass or less, more preferably 10% by mass or less, even more preferably 8% by mass or less, and even more preferably 6% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

[0063] When the topical preparation is a W / O type and contains component (D), the content of component (D) in the topical preparation is preferably 20% by mass or more, more preferably 25% by mass or more, even more preferably 30% by mass or more, from the viewpoint of improving the adhesion suppression effect, and is preferably 70% by mass or less, more preferably 60% by mass or less, even more preferably 50% by mass or less.

[0064] (Content and mass ratio of each component in the case of oil-in-water (O / W) type) When the topical preparation is an O / W type, the content of component (A) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, even more preferably 30% by mass or less, still more preferably 20% by mass or less, and even more preferably 15% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy.

[0065] When the topical preparation is an O / W type, the total content of component (A1), component (A2), and component (A3) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, even more preferably 30% by mass or less, still more preferably 20% by mass or less, and even more preferably 15% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy.

[0066] When the topical preparation is an O / W type, the content of component (B) in the topical preparation is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 1% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect and the topical preparation's usability, such as stickiness, and is preferably 30% by mass or less, more preferably 25% by mass or less, even more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less, from the viewpoint of improving the adhesion-inhibiting effect and the usability of the topical preparation, such as stickiness.

[0067] When the topical preparation is an O / W type, the mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B) / (A)] is, from the viewpoint of improving the adhesion-inhibiting effect, 9 or less, preferably 8 or less, more preferably 6 or less, even more preferably 4 or less, and still more preferably 3 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.05 or more, even more preferably 0.1 or more, and still more preferably 0.2 or more.

[0068] When the topical preparation is an O / W type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 0.01 or more, more preferably 0.05 or more, even more preferably 0.1 or more, and still more preferably 0.2 or more, from the viewpoint of improving the feel when applied to the skin.

[0069] When the topical preparation is an O / W type and contains component (C1), the content of component (C1) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 25% by mass or less, more preferably 20% by mass or less, and even more preferably 16% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion inhibitory effect.

[0070] When the topical preparation is an O / W type and contains component (C2), the content of component (C2) in the topical preparation is preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and even more preferably 1% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 15% by mass or less, more preferably 10% by mass or less, even more preferably 8% by mass or less, and even more preferably 6% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

[0071] When the topical preparation is an O / W type and contains component (D), the content of component (D) in the topical preparation is preferably 0.01% by mass or more, more preferably 0.03% by mass or more, even more preferably 0.05% by mass or more, from the viewpoint of improving the adhesion suppression effect, and is preferably 7% by mass or less, more preferably 5% by mass or less, even more preferably 3% by mass or less.

[0072] [Coating method] In the present invention, the topical preparation can be applied to the skin by a known method depending on the form or purpose of use of the topical preparation. Here, "applying to the skin" includes not only directly applying the topical preparation to the skin surface with the hands, etc., but also attaching the topical preparation to the skin surface by spraying, etc. The topical preparations in the form of liquid, foam, paste, cream, or solid can usually be applied directly by application, spraying, etc.

[0073] (Amount of component (A) applied) The amount of component (A) applied to the skin surface is preferably 0.03 mg / cm from the viewpoint of improving the adhesion suppression effect. 2 More preferably, 0.04 mg / cm 2 More preferably, 0.05 mg / cm 2 More preferably, 0.07 mg / cm 2 From the viewpoint of improving the feeling of use when applied to the skin and from the viewpoint of economy, the amount is preferably 0.8 mg / cm 2 or less, more preferably 0.7 mg / cm 2 More preferably 0.6 mg / cm or less 2 More specifically, the amount of component (A) applied to the skin surface is preferably 0.03 to 0.8 mg / cm from the viewpoint of improving the adhesion-inhibiting effect, improving the feel when applied to the skin, and from the viewpoint of economy. 2 , more preferably 0.04 to 0.8 mg / cm 2 , and more preferably 0.05 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.7 mg / cm 2 , and even more preferably 0.07 to 0.6 mg / cm 2 is.

[0074] When component (A) is one or more selected from component (A1), component (A2), and component (A3), the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 mg / cm from the viewpoint of improving the adhesion-inhibiting effect. 2 More preferably, 0.04 mg / cm 2 More preferably, 0.05 mg / cm 2 More preferably, 0.07 mg / cm 2 From the viewpoint of improving the feeling of use when applied to the skin and from the viewpoint of economy, the amount is preferably 0.8 mg / cm 2 or less, more preferably 0.7 mg / cm 2 More preferably 0.6 mg / cm or less 2More specifically, the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 to 0.8 mg / cm from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to the skin, and economy. 2 , more preferably 0.04 to 0.8 mg / cm 2 , and more preferably 0.05 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.7 mg / cm 2 , and even more preferably 0.07 to 0.6 mg / cm 2 is.

[0075] When the topical preparation is a W / O type, the amount of component (A) applied to the skin surface is preferably 0.03 mg / cm from the viewpoint of improving the adhesion-inhibiting effect. 2 More preferably, 0.04 mg / cm 2 More preferably, 0.05 mg / cm 2 More preferably, 0.07 mg / cm 2 More preferably, 0.10 mg / cm 2 More preferably, 0.20 mg / cm 2 From the viewpoint of improving the feeling of use when applied to the skin and from the viewpoint of economy, the amount is preferably 0.8 mg / cm 2 or less, more preferably 0.7 mg / cm 2 More preferably 0.6 mg / cm or less 2 More specifically, the amount of component (A) applied to the skin surface is preferably 0.03 to 0.8 mg / cm from the viewpoint of improving the adhesion-inhibiting effect, improving the feel when applied to the skin, and from the viewpoint of economy. 2 , more preferably 0.04 to 0.8 mg / cm 2 , and more preferably 0.05 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.8 mg / cm 2 , and even more preferably 0.10 to 0.8 mg / cm 2, and even more preferably 0.20 to 0.7 mg / cm 2 , and even more preferably 0.20 to 0.6 mg / cm 2 is.

[0076] When the topical preparation is a W / O type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 mg / cm from the viewpoint of improving the adhesion-inhibiting effect. 2 More preferably, 0.04 mg / cm 2 More preferably, 0.05 mg / cm 2 More preferably, 0.07 mg / cm 2 More preferably, 0.10 mg / cm 2 More preferably, 0.20 mg / cm 2 From the viewpoint of improving the feeling of use when applied to the skin and from the viewpoint of economy, the amount is preferably 0.8 mg / cm 2 or less, more preferably 0.7 mg / cm 2 More preferably 0.6 mg / cm or less 2 More specifically, the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 to 0.8 mg / cm from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to the skin, and economy. 2 , more preferably 0.04 to 0.8 mg / cm 2 , and more preferably 0.05 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.8 mg / cm 2 , and even more preferably 0.10 to 0.8 mg / cm 2 , and even more preferably 0.20 to 0.7 mg / cm 2 , and even more preferably 0.20 to 0.6 mg / cm 2 is.

[0077] When the topical preparation is an O / W type, the amount of component (A) applied to the skin surface is preferably 0.03 mg / cm from the viewpoint of improving the adhesion-inhibiting effect. 2 More preferably, 0.04 mg / cm 2 More preferably, 0.05 mg / cm 2 More preferably, 0.07 mg / cm 2 From the viewpoint of improving the feeling of use when applied to the skin and from the viewpoint of economy, the amount is preferably 0.8 mg / cm 2 or less, more preferably 0.7 mg / cm 2 More preferably 0.6 mg / cm or less 2 More preferably, 0.3 mg / cm or less 2 More specifically, the amount of component (A) applied to the skin surface is preferably 0.03 to 0.8 mg / cm from the viewpoint of improving the adhesion-inhibiting effect, improving the feel when applied to the skin, and from the viewpoint of economy. 2 , more preferably 0.04 to 0.8 mg / cm 2 , and more preferably 0.05 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.7 mg / cm 2 , and even more preferably 0.07 to 0.6 mg / cm 2 , and even more preferably 0.07 to 0.3 mg / cm 2 is.

[0078] When the topical preparation is an O / W type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 mg / cm from the viewpoint of improving the adhesion-inhibiting effect. 2 More preferably, 0.04 mg / cm 2 More preferably, 0.05 mg / cm 2 More preferably, 0.07 mg / cm 2From the viewpoint of improving the feeling of use when applied to the skin and from the viewpoint of economy, the amount is preferably 0.8 mg / cm 2 or less, more preferably 0.7 mg / cm 2 More preferably 0.6 mg / cm or less 2 More preferably, 0.3 mg / cm or less 2 More specifically, the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 to 0.8 mg / cm from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to the skin, and economy. 2 , more preferably 0.04 to 0.8 mg / cm 2 , and more preferably 0.05 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.8 mg / cm 2 , and even more preferably 0.07 to 0.7 mg / cm 2 , and even more preferably 0.07 to 0.6 mg / cm 2 , and even more preferably 0.07 to 0.3 mg / cm 2 is.

[0079] In addition to the above-described embodiment, the present invention also discloses the following embodiments. <1> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: A method for inhibiting the adhesion of atmospheric hazardous substances, wherein the topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), and the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 0.01 or greater and 9 or less. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Ingredient (B): Ester oil

[0080] <2> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: A method for inhibiting the adhesion of atmospheric hazardous substances, wherein the topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), and the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 0.01 or greater and 9 or less. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Ingredient (B): Ester oil

[0081] <3> The mass ratio [(B) / [(A1)+(A2)+(A3)]] is 0.05 or more and 6 or less. <1> or <2> 2. A method for inhibiting adhesion of atmospheric hazardous substances according to claim 1. <4> The mass ratio [(B) / [(A1)+(A2)+(A3)]] is 0.1 or more and 4 or less, <1> or <2> 2. A method for inhibiting adhesion of atmospheric hazardous substances according to claim 1.

[0082] <5> The total amount of component (A1), component (A2) and component (A3) applied to the skin is 0.03 mg / cm 2 More than 0.8mg / cm 2The above-mentioned <1> ~ <4> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims. <6> The total amount of component (A1), component (A2) and component (A3) applied to the skin is 0.05 mg / cm 2 More than 0.8mg / cm 2 The above-mentioned <1> ~ <4> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims. <7> The total amount of component (A1), component (A2) and component (A3) applied to the skin was 0.07 mg / cm 2 More than 0.7mg / cm 2 The above-mentioned <1> ~ <4> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims.

[0083] <8> The total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 1% by mass or more and 40% by mass or less. <1> ~ <7> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims. <9> The total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 2% by mass or more and 35% by mass or less. <1> ~ <7> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims. <10> The total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 3% by mass or more and 30% by mass or less. <1> ~ <7> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims.

[0084] <11> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 6 or less and 0.05 or more, and the total amount of components (A1), (A2), and (A3) applied to the skin is 0.03 mg / cm 2 More than 0.8mg / cm 2 The following is a method for suppressing the adhesion of atmospheric harmful substances. Component (A1): Average primary particle diameter dA One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Ingredient (B): Ester oil

[0085] <12> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 0.05 or more and 4 or less, and the total amount of components (A1), (A2), and (A3) applied to the skin is 0.03 mg / cm 2 More than 0.8mg / cm 2 The following is a method for suppressing the adhesion of atmospheric harmful substances. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Ingredient (B): Ester oil

[0086] <13> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 0.05 or greater and 6 or less, and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or greater and 40% by mass or less. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 80 nm or less Ingredient (B): Ester oil

[0087] <14> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 0.05 or greater and 4 or less, and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or greater and 40% by mass or less. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Ingredient (B): Ester oil

[0088] <15> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), component (B), and component (C1), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]]] is 4 or less and 0.1 or more, and the mass ratio of the content of component (C1) to the total content of components (A1), (A2), and (A3) in the topical preparation [(C a mass ratio [[(B)+(C1)] / [(A1)+(A2)+(A3)]] of the total content of components (B) and (C1) to the total content of components (A1), (A2), and (A3) in the topical preparation is 4 or less and 0.1 or more, and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Ingredient (B): Ester oil Component (C1): Non-volatile hydrocarbon oil

[0089] <16> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), component (B), and component (C2), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 4 or less and 0.1 or more, and the mass ratio of the content of component (C2) to the total content of components (A1), (A2), and (A3) in the topical preparation [(C2)] a mass ratio [[(B)+(C2)] / [(A1)+(A2)+(A3)]] of the total content of components (B) and (C2) to the total content of components (A1), (A2), and (A3) in the topical preparation, [[(B)+(C2)] / [(A1)+(A2)+(A3)]] is 0.70 or less and 0.03 or more, a mass ratio [[(B)+(C2)] / [(A1)+(A2)+(A3)]] is 4 or less and 0.1 or more, and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Ingredient (B): Ester oil Ingredient (C2): Non-volatile silicone oil

[0090] <17> A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and components (B), (C1), and (C2), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B) / [(A1)+(A2)+(A3)]] is 4 or less and 0.1 or more, and the mass ratio of the content of component (C2) to the total content of components (A1), (A2), and (A3) in the topical preparation [(C2) / [(A1)+(A2)+(A3)]] is 0.70 or less and 0.03 or more, and the components (A1), (A2), and (A3) in the topical preparation are a mass ratio [[(C1) + (C2)] / [(A1) + (A2) + (A3)]] of the total content of components (B), (C1) and (C2) to the total content of components (A1), (A2) and (A3) in the topical preparation, [[(B) + (C1) + (C2)] / [(A1) + (A2) + (A3)]] of the total content of components (B), (C1) and (C2) to the total content of components (A1), (A2) and (A3) in the topical preparation, is 4 or less and 0.1 or more; and the total content of components (A1), (A2) and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less. Component (A1): Average primary particle diameter d A One or more selected from fatty acid-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A2): Average primary particle diameter d A One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Component (A3): Average primary particle diameter d A One or more selected from silicone-treated titanium oxide and zinc oxide, each having a surface area of ​​5 nm or more and 50 nm or less Ingredient (B): Ester oil Component (C1): Non-volatile hydrocarbon oil Ingredient (C2): Non-volatile silicone oil

[0091] <18> The topical preparation is a water-in-oil type, and the total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 10% by mass or more and 40% by mass or less. <11> ~ <17> A method for suppressing the adhesion of harmful substances to the atmosphere. <19> The topical preparation is an oil-in-water type, and the total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 1% by mass or more and 15% by mass or less. <11> ~ <17> A method for suppressing the adhesion of harmful substances to the atmosphere. <20> The content of component (B) in the topical preparation is 1% by mass or more and 18% by mass or less. <11> ~ <19> A method for suppressing the adhesion of harmful substances to the atmosphere. <21> The total amount of component (A1), component (A2) and component (A3) applied to the skin is 0.05 mg / cm 2 More than 0.8mg / cm 2 The above-mentioned <11> ~ <20> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims. <22> The total amount of component (A1), component (A2) and component (A3) applied to the skin was 0.07 mg / cm 2 More than 0.7mg / cm 2 The above-mentioned <11> ~ <20> 10. A method for inhibiting adhesion of atmospheric hazardous substances according to any one of the preceding claims. [Example]

[0092] In the following examples and comparative examples, "parts" and "%" are "parts by mass" and "% by mass" unless otherwise specified.

[0093] (Average primary particle diameter d A ) When component (A) has a shape other than a plate shape, a dispersion of component (A) prepared in advance is placed on the sample stage of a transmission electron microscope (TEM) (manufactured by JEOL Ltd., trade name "JEM1400Plus") and air-dried. After that, the maximum minor axis diameter of 300 primary particles in the image observed by the TEM at a magnification of 50,000 times is measured, and the number average value is used as the average primary particle diameter d A Here, the maximum minor axis refers to the minor axis that has the greatest length among the minor axes perpendicular to the major axis. When component (A) is plate-like, the thicknesses of 300 primary particles in an image observed under the same observation magnification conditions as above are measured, and the number average value is calculated as the average primary particle diameter d A It was decided. The dispersion of component (A) was prepared by adding 95 g of ethanol as a solvent to 5 g of component (A) and subjecting the mixture to ultrasonic dispersion.

[0094] (Kinematic viscosity at 25°C) The kinematic viscosity at 25°C was measured using an Ubbelohde viscometer in accordance with ASTM D 445-46T or JIS Z 8803.

[0095] In the examples and comparative examples, commercially available products of component (A) shown in Table 1 below were used.

[0096] [Table 1]

[0097] Examples 1 to 13, Comparative Examples 1 to 8, Reference Examples 1 to 4 The components (A) or (A'), (B) and (D) were mixed at room temperature with stirring according to the compositions shown in Tables 2 to 6 to obtain the topical preparations of Examples 1 to 13 and Comparative Examples 1 to 8. Component (B) is isopropyl palmitate (manufactured by Kao Corporation, trade name "Exepar IPP"), and component (D) is dodecamethylpentasiloxane (manufactured by Shin-Etsu Chemical Co., Ltd., trade name "KF-96L-2cs", kinematic viscosity at 25°C: 2 mm 2 / s) was used. Furthermore, as component (A'), a methylsiloxane network polymer ("Tospearl 145A" manufactured by Momentive Performance Materials Japan, LLC (spherical silicone microparticles, average particle size: 4.5 μm (catalog value))) and silica particles ("Sunsphere NP-30" manufactured by AGC Si-Tech Co., Ltd. (average particle size: 4 μm (catalog value))) were used. In Reference Examples 1 to 4, component (B) was not used, and component (A) and component (D) were stirred and mixed to form the compositions shown in Tables 2 to 5, and used as external preparations. The obtained topical preparations were evaluated for their effect of inhibiting the adhesion of air hazardous substances by the following method, and the results are shown in Tables 2 to 6.

[0098] <Method for evaluating the effect of suppressing the adhesion of atmospheric hazardous substances> The topical preparation obtained above was applied in an amount of 0.12 mg / cm of component (A) or component (A'). 2 The solution was applied to white artificial leather (trade name "Laforet S2923", manufactured by Okamoto Shinwa Co., Ltd.) as a skin substitute so that the above-mentioned consistency was achieved, and the solution was left to dry overnight at room temperature. The artificial leather surface to which the topical agent was applied was exposed to an airborne environment containing the harmful atmospheric substances to be evaluated, and the L * a * b * The value was measured, and the color difference ΔE before and after exposure was measured by the following method. [Measurement of color difference ΔE] Using a colorimeter (product name "CM-2002", manufactured by Konica Minolta, Inc.), the L1 * , a1 * , b1 * The values ​​were measured. Separately, a fan (product name "Silky Wind 9ZF002RH02", size: 129 × 106 × 83 mm, manufactured by Rhythm Watch Co., Ltd.) and a mesh sieve (Test sieves JIS Z 8801, frame dimensions: φ100 × 45H, mesh size: 106 μm, manufactured by Tokyo Screen Co., Ltd.) were fixed inside a glove bag (product number "3-118-01", manufactured by AS ONE Corporation). The mesh sieve was installed at a height of 17 cm. A piece of artificial leather (5 cm x 4 cm) coated with the test sample topical agent was attached to a support so that the bottom edge of the artificial leather was at a height of 11 cm. The distance between the coated surface of the artificial leather on the support and the air blower was 15 cm, and the air blower was set so that the coated surface of the artificial leather was perpendicular to the direction of airflow from the air blower, and the center height of the air blower blades was the same as the center height of the artificial leather. The temperature inside the glove bag was set to 25°C and the relative humidity to 57%RH, and 50 mg of graphite powder (trade name "J-CPB", average particle size: 5.5 μm, manufactured by Nippon Graphite Industries Co., Ltd.) was classified as the air hazardous substance to be evaluated using a mesh sieve de-clogging brush (trade name "JNB-5", brush diameter 53 μm, manufactured by Tokyo Screen Co., Ltd.) and dropped in front of the outlet of a blower with the air blowing scale set to 1 for 1 minute, exposing the surface of the artificial leather to which the topical agent had been applied to the air hazardous substance to be evaluated. Next, the L2 of the exposed artificial leather surface was measured using the colorimeter. * , a2 * , b2 * The values ​​were measured, and the color difference ΔE value was calculated using the following formula (I). ΔE=[(L1 * -L2 * ) 2 +(a1 * -a2 * ) 2 +(b1 * -b2 * ) 2 ] 0.5 (I) The above procedure was carried out three times for each test sample, and the average value of the color difference ΔE of the artificial leather coated with the topical agent of the test sample was taken as ΔEt. Furthermore, the same procedure as above was carried out three times for artificial leather not coated with the topical agent as a standard sample, and the average value of the color difference ΔE was taken as ΔEs, and the adhesion inhibition rate was calculated using the following formula (II). The higher the adhesion inhibition rate, the better the effect of inhibiting the adhesion of atmospheric harmful substances. Air hazardous substance adhesion suppression rate (%) = 100 × (ΔEs - ΔEt) / ΔEs (II)

[0099] [Table 2]

[0100] [Table 3]

[0101] [Table 4]

[0102] [Table 5]

[0103] [Table 6]

[0104] From Tables 2 to 6, it can be seen that Examples 1 to 13 have a higher adhesion suppression effect than Comparative Examples 1 to 8 by applying an external preparation containing component (A) and component (B) in which the mass ratio of component (B) to component (A) [(B) / (A)] is 9 or less. Furthermore, compared to Reference Examples 1 to 4, the topical preparations of Examples 1 to 13 contain component (B), and therefore have a good feel (touch) when used.

[0105] Examples 14 to 21 The topical preparations shown in the following Formulation Examples 1 to 8 were prepared, and each topical preparation was administered at a dose of 2 mg / cm. 2 The evaluation was carried out in the same manner as in the evaluation of the effect of inhibiting adhesion of atmospheric hazardous substances, except that the above-mentioned composition was applied to white artificial leather. The results are shown in Table 7. The notations in the prescription examples are as follows: *1: Sakai Chemical Industry Co., Ltd. "STR-100C-LF" *2: "MICRO ZINC OXIDE MZ-504R3M" manufactured by Teika Corporation *3: "Estemol N-01" manufactured by Nisshin Oillio Group Co., Ltd. *4: NOF Corporation "Pearleam EX" *5: "Nikkol Squalane" manufactured by Nippon Surfactant Industries Co., Ltd. *6: Shin-Etsu Chemical Co., Ltd. "KF-96A-10CS" *7: Kao Corporation "Sphingolipid E" *8: Shin-Etsu Chemical Co., Ltd. "KF-6015" *9: Shin-Etsu Chemical Co., Ltd. "KF-96L-2CS" *10: "Tospearl 145A" manufactured by Momentive Performance Materials Japan, LLC *11: "SI-Talc JA-46R" manufactured by Miyoshi Kasei Co., Ltd. *12: Kao Corporation's "Excepearl TGO" *13: Shin-Etsu Chemical Co., Ltd. "KF-96A-6CS" *14: Sakai Chemical Industry Co., Ltd. "FINEX-30-OTS(K)" *15: BASF Japan Ltd. "Uvinal MC80" *16: BASF Japan Ltd. "TINOSORB S" *17: Kao Corporation's "Excepearl IPP" *18: "Silicone TSF405A" manufactured by Momentive Performance Materials Japan, LLC *19: Ishihara Sangyo Kaisha "MPT-171" *20: "Cetyl Alcohol NX" manufactured by Kokyu Alcohol Kogyo Co., Ltd. *21: "Montex A" manufactured by Miyoshi Oil & Fats Co., Ltd. *22: Kao Corporation "Emulgen 1620G" *23: “PEMULETR-1” manufactured by Lubrizol Advanced Materials, Inc. *24: “PEMULENTSR-2” manufactured by Lubrizol Advanced Materials, Inc. *25: Sakai Chemical Industry Co., Ltd. "STR-100W-OTS" *26: BASF Japan Ltd. "Uvinal T150" *27: Kao Corporation "Leodor TW-S120V" *28: NOF Corporation "Pearleam 4" *29: Sakai Chemical Industry Co., Ltd. "FINEX-50-LPTM" *30: "D-FZN (SI01)" manufactured by Daito Kasei Kogyo Co., Ltd. *31: "Cosmol 525" manufactured by Nisshin Oillio Group Co., Ltd. *32: BASF Japan Ltd. "Uvinal A Plus GRANULAR" *33:Kao Corporation "Leodor SP-S10V" *34: "SIMULGEL EG" manufactured by SEPPIC SA *35: "Silicone X-52-1621" manufactured by Shin-Etsu Chemical Co., Ltd. *36: "Salacos 99" manufactured by Nisshin Oillio Group Co., Ltd.

[0106] Prescription Example 1 (W / O type topical agent, mass ratio [(B) / (A)] = 0.12, mass ratio [(C1) / (A)] = 0.35) (Ingredients (amount)) Stearic acid-treated titanium dioxide (ingredient (A1))*1 7 parts Silicone-treated zinc oxide (ingredient (A3))*2 19 parts Neopentyl glycol dicaprate (ingredient (B))*3 3 parts Liquid isoparaffin (component (C1))*4 6 parts Squalane (ingredient (C1))*5 3 parts N-(hexadecyloxyhydroxypropyl)-N-hydroxyethylhexadecanamide*7 1.5 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5)*8 1.4 parts Dodecamethylpentasiloxane (25°C kinematic viscosity: 2mm 2 / s)(Component (D))*9 40.1 parts Methylsiloxane network polymer*10 1 part Silicone-coated talc*11 1.9 parts Glycerin (86%) 1 part Purified water Remaining part Total 100 copies

[0107] Prescription Example 2 (W / O type external preparation, mass ratio [(B) / (A)] = 0.31, mass ratio [(C1) / (A)] = 0.35, mass ratio [(C2) / (A)] = 0.04) (Ingredients (amount)) Stearic acid-treated titanium dioxide (ingredient (A1))*1 7 parts Silicone-treated zinc oxide (ingredient (A3))*2 19 parts Neopentyl glycol dicaprate (ingredient (B))*3 3 parts Glyceryl tri-2-ethylhexanoate (ingredient (B))*12 5 parts Liquid isoparaffin (component (C1))*4 5 parts Squalane (ingredient (C1))*5 4 parts Dimethylpolysiloxane (25°C kinematic viscosity: 10mm 2 / s)(Component (C2))*6 1 part N-(hexadecyloxyhydroxypropyl)-N-hydroxyethylhexadecanamide*7 1.5 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5)*8 1.4 parts Dodecamethylpentasiloxane (25°C kinematic viscosity: 2mm 2 / s)(Component (D))*9 35.1 parts Methylsiloxane network polymer*10 3 parts Silicone-coated talc*11 1.9 parts Glycerin (86%) 1 part Purified water Remaining part Total 100 copies

[0108] Prescription Example 3 (W / O type topical agent) (mass ratio [(B) / (A)] = 0.12, mass ratio [(C1) / (A)] = 0.35, mass ratio [(C2) / (A)] = 0.23) (Ingredients (amount)) Stearic acid-treated titanium dioxide (ingredient (A1))*1 7 parts Silicone-treated zinc oxide (ingredient (A3))*2 19 parts Neopentyl glycol dicaprate (ingredient (B))*3 3 parts Liquid isoparaffin (component (C1))*4 7 parts Squalane (ingredient (C1))*5 2 parts Dimethylpolysiloxane (25°C kinematic viscosity: 10mm 2 / s)(Component (C2))*6 1 part Dimethylpolysiloxane (25°C kinematic viscosity: 6mm 2 / s)(Component (C2))*13 5 parts N-(Hexadecyloxyhydroxypropyl)-N-hydroxyethylhexadecanamine*7 1.5 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5)*8 1.4 parts Dodecamethylpentasiloxane (25°C kinematic viscosity: 2mm 2 / s)(Component (D))*9 35.1 parts Glycerin (86%) 1 part Purified water Remaining part Total 100 copies

[0109] Prescription Example 4 (W / O type topical agent, mass ratio [(B) / (A)] = 0.97, mass ratio [(C2) / (A)] = 0.27) (Ingredients (amount)) Octyltriethoxysilane-treated zinc oxide (ingredient (A2))*14 15 parts 2-Ethylhexyl paramethoxycinnamate (ingredient (B))*15 10 parts Neopentyl glycol dicaprate (ingredient (B))*3 3 parts Isopropyl palmitate (ingredient (B))*17 1.5 parts Dimethylpolysiloxane (25°C kinematic viscosity: 6mm 2 / s)(Component (C2))*13 4 parts 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine*16 2 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5)*8 0.8 parts Dodecamethylpentasiloxane (25°C kinematic viscosity: 2mm 2 / s)(Component (D))*9 5 parts Decamethylcyclopentasiloxane (25°C kinematic viscosity: 4mm 2 / s)(Component (D))*18 28.7 parts Silicone-coated talc*11 2 parts 11 parts ethanol 1,3-butylene glycol 2 parts Purified water Remaining part Total 100 copies

[0110] Formulation Example 5 (O / W type topical agent, mass ratio [(B) / (A)] = 3.0, mass ratio [(C2) / (A)] = 0.25) (Ingredients (amount)) Stearic acid-treated titanium dioxide (ingredient (A1))*19 4 parts Isopropyl palmitate (ingredient (B))*17 4 parts 2-Ethylhexyl paramethoxycinnamate (ingredient (B))*15 8 parts Dimethylpolysiloxane (25°C kinematic viscosity: 10mm 2 / s)(Component (C2))*6 1 part 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine*16 1 part Cetanol*20 0.2 parts Glyceryl monostearate*21 0.3 parts Isoceteth-20*22 0.03 parts (Acrylates / C10-30 alkyl acrylate) crosspolymer*23 0.2 parts (Acrylates / C10-30 alkyl acrylate) crosspolymer*24 0.2 parts EDTA-2Na 0.01 part Phenoxyethanol 0.5 parts Potassium hydroxide (48%) 0.4 parts 5 parts ethanol Purified water Remaining part Total 100 copies

[0111] Formulation Example 6 (O / W type topical agent, mass ratio [(B) / (A)] = 3.5, mass ratio [(C2) / (A)] = 0.25) (Ingredients (amount)) Octyltriethoxysilane-treated titanium dioxide (ingredient (A2))*25 4 parts Isopropyl palmitate (ingredient (B))*17 4 parts 2-Ethylhexyl paramethoxycinnamate (ingredient (B))*15 8 parts 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1, 3,5-triazine (ingredient (B))*26 2 parts Dimethylpolysiloxane (25°C kinematic viscosity: 10mm 2 / s)(Component (C2))*6 1 part 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine*16 2 parts Cetanol*20 0.2 parts Glyceryl monostearate*21 0.3 parts Isoceteth-20*22 0.03 parts Polyoxyethylene sorbitan monostearate*27 0.1 parts (Acrylates / C10-30 alkyl acrylate) crosspolymer*23 0.2 parts (Acrylates / C10-30 alkyl acrylate) crosspolymer*24 0.2 parts Light liquid isoparaffin (component (D))*28 1 part EDTA-2Na 0.01 part Phenoxyethanol 0.5 parts 1,3-butylene glycol 5 parts Potassium hydroxide (48%) 0.6 parts 5 parts ethanol Purified water Remaining part Total 100 copies

[0112] Formulation Example 7 (O / W type topical preparation, mass ratio [(B) / (A)] = 1.3) (Ingredients (amount)) Silicone-treated zinc oxide (ingredient (A3))*29 8 parts Silicone-treated zinc oxide (ingredient (A3))*30 3 parts Neopentyl glycol di-2-ethylhexanoate (ingredient (B))*31 4 parts 2-Ethylhexyl paramethoxycinnamate (ingredient (B))*15 8 parts Diethylaminohydroxybenzoylbenzoic acid hexyl ester (ingredient (B))*32 2 parts 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine*16 2 parts Behenyl alcohol 0.5 parts Sorbitan monostearate*33 1 part Polyoxyethylene sorbitan monostearate*27 1 part Sodium acrylate / sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80*34 2 parts Methylsiloxane network polymer*35 0.5 parts 1,3-butylene glycol 1 part EDTA-2Na 0.01 part 10 parts ethyl alcohol Purified water Remaining part Total 100 copies

[0113] Formulation Example 8 (O / W type topical agent, mass ratio [(B) / (A)] = 1.5, mass ratio [(C2) / (A)] = 0.50) (Ingredients (amount)) Stearic acid-treated titanium dioxide (ingredient (A1))*19 8 parts Isononyl isononanoate (ingredient (B))*36 7.6 parts Neopentyl glycol dicaprate (ingredient (B))*3 4 parts Dimethylpolysiloxane (25°C kinematic viscosity: 6mm 2 / s)(Component (C2))*13 4 parts Sorbitan monostearate*33 0.7 parts Polyoxyethylene sorbitan monostearate*27 1 part 1 part stearyl alcohol (Acrylates / C10-30 alkyl acrylate) crosspolymer*23 0.07 parts (Acrylates / C10-30 alkyl acrylate) crosspolymer*24 0.25 parts Potassium hydroxide (48%) 0.4 parts 1,3-butylene glycol 8 parts EDTA-2Na 0.02 part Purified water Remaining part Total 100 copies

[0114] [Table 7]

[0115] From Table 7, it can be seen that in Examples 14 to 21, application of the topical preparations shown in Formulation Examples 1 to 8 has an adhesion inhibitory effect. Furthermore, compared to Reference Examples 1 to 4, the topical preparations used in Examples 14 to 21 contain component (B), and therefore have a good feel (touch) when used. [Industrial Applicability]

[0116] The adhesion inhibiting method of the present invention is highly effective in inhibiting the adhesion of atmospheric hazardous substances, and is therefore particularly useful as a method for inhibiting the adhesion of atmospheric hazardous substances to the skin. [Explanation of symbols]

[0117] 1: Sample to be evaluated 2:Support 3: Mesh sieve 4: Air hazardous substances for evaluation 5: Blower

Claims

1. A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising: The topical preparation contains the following components (A), (B), and (C), and the component (C) is one or more selected from the following components (C1) and (C2): The content of component (A) in the topical preparation is 1% by mass or more and 40% by mass or less, the mass ratio [(B) / (A)] of the content of component (B) to the content of component (A) in the topical preparation is 0.1 or more and 9 or less; When the topical preparation contains component (C1), the mass ratio of the content of component (C1) to the content of component (A) in the topical preparation [(C1) / (A)] is 0.1 or more and 3.5 or less; When the topical preparation contains component (C2), the mass ratio of the content of component (C2) to the content of component (A) in the topical preparation [(C2) / (A)] is 0.01 or more and 0.70 or less; The amount of component (A) applied to the skin is 0.8 mg / cm 2 or less. A method for suppressing the adhesion of harmful substances to the atmosphere. Component (A): Average primary particle diameter d A A hydrophobized metal oxide having a surface roughness of 5 nm or more and 50 nm or less, which is at least one metal oxide selected from titanium oxide and zinc oxide. Component (B): Ester oil Component (C): A non-volatile oil other than component (B). Component (C1): Non-volatile hydrocarbon oil Component (C2): Non-volatile silicone oil

2. The amount of component (A) applied to the skin was 0.03 mg / cm 2 The method for inhibiting adhesion of atmospheric hazardous substances according to claim 1 .

3. A method for inhibiting adhesion of atmospheric hazardous substances to the skin by applying a topical agent to the skin, the method comprising: The topical preparation contains the following components (A), (B), and (C), and the component (C) is one or more selected from the following components (C1) and (C2): the mass ratio [(B) / (A)] of the content of component (B) to the content of component (A) in the topical preparation is 0.1 or more and 9 or less; When the topical preparation contains component (C1), the mass ratio of the content of component (C1) to the content of component (A) in the topical preparation [(C1) / (A)] is 0.1 or more and 3.5 or less; When the topical preparation contains component (C2), the mass ratio of the content of component (C2) to the content of component (A) in the topical preparation [(C2) / (A)] is 0.01 or more and 0.70 or less. A method for suppressing the adhesion of harmful substances to the atmosphere. Component (A): One or more hydrophobized metal oxides selected from the following components (A1), (A2), and (A3), which are at least one metal oxide selected from titanium oxide and zinc oxide. Component (A1): Average primary particle diameter d A A fatty acid-treated metal oxide having a diameter of 5 nm or more and 50 nm or less. Component (A2): Average primary particle diameter d A Alkylalkoxysilane-treated metal oxide having a diameter of 5 nm or more and 50 nm or less Component (A3): Average primary particle diameter d A Silicone-treated metal oxide having a thickness of 5 nm or more and 50 nm or less Component (B): Ester oil Component (C): A non-volatile oil other than component (B). Component (C1): Non-volatile hydrocarbon oil Component (C2): Non-volatile silicone oil

4. 4. A method for suppressing adhesion of atmospheric hazardous substances as described in claim 3, wherein the mass ratio [(B) / [(A1)+(A2)+(A3)]] of the content of component (B) to the total content of components (A1), (A2) and (A3) in the topical preparation is 0.1 or more and 9 or less.

5. The total amount of component (A1), component (A2), and component (A3) applied to the skin is 0.03 mg / cm 2 The method for inhibiting adhesion of atmospheric hazardous substances according to claim 3 or 4.

6. The method for suppressing adhesion of atmospheric hazardous substances according to any one of claims 3 to 5, wherein the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less.

7. The total amount of component (A1), component (A2), and component (A3) applied to the skin was 0.8 mg / cm 2 7. The method for inhibiting adhesion of atmospheric hazardous substances according to claim 5 or 6, wherein:

Images